



---

One North End Avenue · Suite 1111 · New York · New York 10282  
Telephone: (877) 898-8038 (212) 791-2911 Fax: 212-791-2917  
150 Fairway Drive · Suite 150 · Vernon Hills · Illinois 60061  
Telephone: (847) 573-0033 · Facsimile: (847) 573-8288  
(Amex-IMM)

CONTACT: Dina Grinshpun: 877-898-8038

## **ARBITRAL TRIBUNAL FINDS FOR IMMTECH**

Vernon Hills, IL, June 12, 2006 - Immtech Pharmaceuticals, Inc. (AMEX: IMM) announced today that on June 9, 2006 the International Court of Arbitration of the International Chamber of Commerce notified the parties of a decision by the Arbitral Tribunal in Immtech's arbitration against Neurochem, Inc. and Neurochem International, Inc. ("Neurochem"). The Arbitral Tribunal awarded Immtech approximately \$1.9 million in damages and attorneys' fees and costs, stating that Immtech was "the only party to prevail on any of its claims" and that "Neurochem prevailed on none of its counterclaims." The Arbitral Tribunal also found that Neurochem committed numerous breaches of the Confidentiality, Testing and Option Agreement between Immtech and Neurochem.

On August 12, 2003, the Company filed a lawsuit against Neurochem alleging that Neurochem, among other things, breached the Confidentiality, Testing and Option Agreement when Neurochem filed a series of patent applications relating to the use of compounds provided to Neurochem by Immtech. Neurochem's patent applications related to the use of some Immtech compounds for treating amyloid diseases such as Alzheimer's. Pursuant to the terms of the Agreement, Neurochem agreed to keep compounds and information that Immtech provided confidential and not to disclose or exploit such information without Immtech's prior written consent. The Arbitral Panel determined that Neurochem breached provisions of the Agreement, "substantively, and substantially."

Immtech's lawsuit against Neurochem was stayed in 2004 and Immtech's claims were referred to the ICC International Court of Arbitration for resolution. The arbitration hearing was held in September 2005.

The Arbitral Tribunal made the following findings.

- Neurochem breached Section 3 of the Agreement by including structural information and results of testing of Immtech compounds in patent applications and by permitting those patent applications to be published.
- Neurochem breached Section 4 of the Agreement by including the results of testing of Immtech compounds in the Neurochem patent applications and by permitting those patent applications to be published.

- Neurochem breached Section 6.1(c) of the Agreement by failing to pay a progress payment under the Agreement.

Eric L. Sorkin, Chairman and Chief Executive Officer stated, “Even though this conflict with Neurochem was in no way related to our core business in the development and commercialization of Immtech compounds to treat infectious diseases, we are still pleased that the Arbitral Tribunal recognized Neurochem’s substantial breach of the Agreement. Although we are not currently actively engaged in drug development for Alzheimer’s or any other amyloid diseases, we are pleased that the Arbitral Tribunal recognized we are not “blocked from benefiting monetarily from use of Immtech’s compounds for amyloid research.” Indeed, the vast majority of our proprietary compounds have been patented or are claimed in pending patent applications. If any other company decides to use any of our compounds, that company will have to seek a relationship with us and to compensate us accordingly.”

### **About Immtech Pharmaceuticals**

Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases, and the Company is expanding targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new treatments for malaria, Pneumocystis pneumonia and African sleeping sickness (Trypanosomiasis) and drug development programs for fungal infections, hepatitis C, and tuberculosis. The Company has worldwide licensing and exclusive commercialization rights to a large library of well-defined compounds from which a pipeline of therapeutic products could be developed. For additional information, please go to <http://www.immtechpharma.com>.

“Safe Harbor” Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech International, Inc.’s business which are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s Annual Report on Form 10-K for the most recently ended fiscal year.